{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["49(1)"],"submitter":["Garrick A"],"funding":["Colorado State University"],"pubmed_abstract":["The purpose of this study was to evaluate the pharmacokinetics of oral (PO) ondansetron compared to intravenous (IV) ondansetron in eight healthy client-owned dogs. Dogs were randomized to one of two protocols in a crossover design, receiving PO or IV ondansetron at a dose of 1 mg/kg on Day 0 and the opposite formulation at an equal dose on Day 7. Plasma was collected at baseline and 1, 2, 4, and 8 h post administration. Ondansetron concentrations were measured utilizing liquid chromatography/mass spectrometry. For IV administration, AUC<sub>0-8h</sub> was 1181 ± 619 ng/mL*h, with all dogs having detectable plasma concentrations at all time points. For PO administration, mean C<sub>max</sub> was 22 ± 11.3 ng/mL and AUC<sub>0-8h</sub> was 61.7 ± 45.4 ng/mL*h, with all dogs having undetectab"],"journal":["Journal of veterinary pharmacology and therapeutics"],"pagination":["17-21"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12796776"],"repository":["biostudies-literature"],"pubmed_title":["Bioavailability of Oral Ondansetron in Dogs: A Crossover Study."],"pmcid":["PMC12796776"],"pubmed_authors":["Diaz A","Gustafson D","Garrick A","Quimby J","Shropshire S","Zersen K"],"additional_accession":[]},"is_claimable":false,"name":"Bioavailability of Oral Ondansetron in Dogs: A Crossover Study.","description":"The purpose of this study was to evaluate the pharmacokinetics of oral (PO) ondansetron compared to intravenous (IV) ondansetron in eight healthy client-owned dogs. Dogs were randomized to one of two protocols in a crossover design, receiving PO or IV ondansetron at a dose of 1 mg/kg on Day 0 and the opposite formulation at an equal dose on Day 7. Plasma was collected at baseline and 1, 2, 4, and 8 h post administration. Ondansetron concentrations were measured utilizing liquid chromatography/mass spectrometry. For IV administration, AUC<sub>0-8h</sub> was 1181 ± 619 ng/mL*h, with all dogs having detectable plasma concentrations at all time points. For PO administration, mean C<sub>max</sub> was 22 ± 11.3 ng/mL and AUC<sub>0-8h</sub> was 61.7 ± 45.4 ng/mL*h, with all dogs having undetectab","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T15:27:18.743Z","creation":"2026-06-01T03:10:46.273Z"},"accession":"S-EPMC12796776","cross_references":{"pubmed":["40924364"],"doi":["10.1111/jvp.70024"]}}